Open Access

Elevated pleural effusion IL-17 is a diagnostic marker and outcome predictor in lung cancer patients

European Journal of Medical Research201419:23

https://doi.org/10.1186/2047-783X-19-23

Received: 20 February 2014

Accepted: 2 April 2014

Published: 8 May 2014

Abstract

Background

Interleukin 17 (IL-17) is a proinflammatory cytokine produced mainly by CD4+ T-lymphocytes and may be important in tumor cell growth and progression. In this study, we aimed to evaluate the diagnostic and prognostic value of pleural effusion levels of IL-17 in lung cancer patients with malignant pleural effusion (MPE).

Methods

Pleural effusion samples were collected from 78 lung cancer patients with MPE and from 45 patients with nonmalignant pleural effusion. Pleural fluid concentrations of IL-17 were measured by using enzyme-linked immunosorbent assays.

Results

Malignant effusion exhibited higher IL-17 levels than nonmalignant effusion (20.49 ± 5.27 pg/ml vs. 13.16 ± 2.25 pg/ml; P < 0.01). Lung cancer patients with pleural fluid IL-17 levels below 15 pg/ml had longer overall survival than those patients with higher levels (10.8 months vs. 4.7 months; P < 0.05). On the basis of multivariate analysis, we found that pleural fluid IL-17 level was an independent prognostic factor in lung cancer patients with MPE.

Conclusions

Measurement of IL-17 levels might be a useful diagnostic and prognostic test for lung cancer patients with MPE.

Background

Lung cancer is the leading cause of cancer-related mortality in the world [1]. Approximately 15% of lung cancer patients have pleural effusion at the time of initial diagnosis, and 50% develop it later in the course of their disease [2]. Differentiating malignant from nonmalignant pleural effusion is a critical problem, and conventional methods have proven inadequate [36]. Pleural fluid cytology has traditionally been the analytical method of choice for the detection of tumor cells in pleural fluid. However, sensitivity varies between 30% and 60% [7], and blindly obtained pleural needle biopsy specimens offer little additional sensitivity [8]. Although the presence of tumor cells in pleural effusion is a diagnostic marker of malignant pleural effusion (MPE), the probability of finding them is low. For negative cytology pleural effusion, some of the currently used indices, such as carcinoembryonic antigen, neuron-specific enolase and cytokeratin 19 fragments (CYFRA 21-1), have a certain extent of differential value; however, their specificity and sensitivity are limited [9, 10]. Therefore, searching for new indices is very important.

In addition to diagnostic issues, patients with MPE have a poor prognosis and are difficult to treat effectively [11]. Despite advances in treatment modalities, the overall survival (OS) is still very short. The present standard treatment is to evacuate the pleural fluid, followed by intravenous chemotherapy or intrapleural chemotherapy [12]. However, it was found that not all patients were benefited from the addition of chemotherapy, especially in patients with short OS. Therefore, prognostic assessment of the patient is essential. Hsu et al. proved that the expression level of angiogenetic biomarkers was significantly correlated with patient survival and pleural effusion control [13]. In addition, researchers in recent molecular and genetic profiling studies identified several markers as diagnostic and prognostic factors of lung cancer.

The improved understanding of pleural effusion immunopathogenesis could lead to the development of immunodiagnostic tools to facilitate its differential diagnosis. Investigators in large-scale studies have reported that lymphocytes play an important role in the pathogenesis of pleural effusion [1417]. CD4+ T cells can be differentiated into interleukin 17 (IL-17)-producing T helper (Th17) cells. Th17 cells produce unique cytokines, including IL-17A, IL-17F and IL-22. These cytokines play a role in inflammation and cancers [1821]. In previous studies, researchers have reported that the levels of IL-17 are elevated in pleural effusion [22, 23]. However, whether there is a significant difference in their expression level as well as in the relationship between pleural fluid IL-17 concentrations and the prognosis for patients with lung cancer have not been evaluated to date.

In our present study, we assessed pleural effusion of various etiologies in 123 patients to determine whether IL-17 pleural fluid could be used as a diagnostic indicator of lung cancer and a predictor of survival time. We found that IL-17 is elevated in malignant effusion caused by lung cancer, as well as being potentially predictive of survival outcome.

Methods

Patients

The study included 123 consecutive patients with pleural effusion who were recruited from the Nanjing Chest Hospital from January 2009 to December 2010. All cases of pleural effusion had a definite etiology documented by examination of effusion biochemistry, cytology, pleural biopsy, percutaneous biopsy, endoscopic examination and clinical follow-up. The characteristics of the patients are summarized in Table 1. The patient group included 70 men and 53 women with a median age of 65 years. Of the total sample, 78 patients (63.4%) had MPE and 45 (36.6%) had nonmalignant pleural effusion. The OS time in patients with MPE was measured from the time of diagnosis to the date of death or the last follow-up.
Table 1

Patient characteristics a

Variables

MPE

BPE

P-value

Patients, n

78

45

 

Mean age (±SD), years

56.3 ± 12.5

55.6 ± 11.7

>0.05

Male/female

36/42

34/11

>0.05

MPE

   

  Adenocarcinoma

67

ND

 

  Squamous cell carcinoma

5

ND

 

  Small-cell lung carcinoma

6

ND

 

BPE

   

  Tuberculous

ND

28

 

  Parapneumonic

ND

12

 

  Heart failure

ND

5

 

Diagnostic method

   

  Biochemistry

ND

30

 

  Cytology

50

ND

 

  Pleural biopsy

6

8

 

  Percutaneous biopsy

12

4

 

  Endoscopic examination

10

3

 

aBPE, Benign pleural effusion; MPE, Malignant pleural effusion; ND, No data.

This study was approved by the Ethics Committee of Nanjing Chest Hospital, and informed consent was obtained from each patient.

Diagnostic criteria for pleural effusion

The diagnostic criteria for MPE were as follows. Cytological evidence of malignant cells present in pleural effusion or in biopsy specimens. Tuberculous (TB) pleural effusion was diagnosed according to the following findings: identification of acid-fast bacilli in pleural fluid, caseous granulomas in a pleural biopsy specimen and a high level of pleural fluid adenosine deaminase (>40 U/L) with an improvement of the pleurisy after anti-TB therapy. Parapneumonic effusion was characterized by any pleural effusion associated with pneumonia and response to antibiotics. Patients with pleural empyema were also included in this group. Effusions related to heart failure were collected from patients with documented heart failure but without neoplastic or other disease.

Sample collection and determination of IL-17 concentration

Fresh pleural effusion specimens were collected before treatment and centrifuged at 1,500 × g for 10 minutes at -4°C. The supernatants were immediately stored at -80°C until use. The IL-17 concentrations were determined by enzyme-linked immunosorbent assay (ELISA) with the commercial human IL-17 Ready-SET-Go! ELISA Kit (eBioscience, San Diego, CA, USA). All assays were run in duplicate, with dilutions as appropriate, and the technicians were blinded to clinical data.

Statistical analyses

All statistical analyses of differences between malignant effusions and nonmalignant pleural effusion were performed using the Mann–Whitney U test. The diagnostic accuracy of IL-17 in discriminating between lung cancer with malignant and nonmalignant pleural effusion was compared by constructing receiver operating characteristic (ROC) curves. The optimum cutoff point from the ROC analysis was established by selecting the value that provided the greatest sum of sensitivity and specificity. Survival analyses were performed using the Kaplan–Meier method, and significant differences in survival rates were compared using the logrank test. The Cox proportional hazards regression model was used to compare the relative influence of different prognostic factors. P < 0.05 was considered to indicate statistical significance.

Results

Levels of IL-17 in pleural effusion

As shown in Figure 1, patients with malignant effusion exhibited higher IL-17 concentration than those with nonmalignant pleural effusion (20.49 ± 5.27 pg/ml vs. 13.16 ± 2.25 pg/ml; P = 0.004). Pleural fluid IL-17 concentrations in patients with malignant effusion were higher than in patients with TB effusion (20.49 ± 5.27 pg/ml vs. 17.43 ± 5.39 pg/ml; P = 0.021).
Figure 1

Levels of interleukin 17 in pleural effusion. Malignant effusion exhibited higher interleukin 17 (IL-17) concentrations than in nonmalignant effusion and tuberculous effusion. *compared with nonmalignant effusion group and TB effusion group, P < 0.05 for both.

Diagnostic value of IL-17 in malignant pleural effusion

ROC curve analysis was carried out to assess the IL-17 concentrations in patients with MPE. The area under the ROC curve was 0.724 (95% confidence interval = 0.635 to 0.812). The best efficacy was observed at 15 pg/ml. Using a cutoff value of 15 pg/ml, IL-17 had a sensitivity of 79.5% (62 of 78 patients), specificity of 91.1% (41 of 45 patients), accuracy of 83.7% (103 of 123 patients), positive predictive value of 93.9% (62 of 66 patients) and negative predictive value of 71.9% (41 of 57 patients) (Figure 2).
Figure 2

Receiver operating characteristic curve of interleukin 17 for the differential diagnosis of malignant and nonmalignant effusion. ROC, Receiver operating characteristic.

Relationship between IL-17 concentration and clinicopathological factors in lung cancer patients with malignant pleural effusion

After we confirmed that the IL-17 concentration was elevated in patients with MPE, we sought possible relationships between IL-17 and gender, age, histologic type of tumor, cancer stage, Eastern Cooperative Oncology Group performance status (ECOG PS), positive cytologic examination and location of pleural effusion. As shown in Table 2, we found no significant correlation between IL-17 concentration and any of these clinicopathological factors.
Table 2

Interleukin 17 levels in pleural effusion of lung cancer patients a

Clinical variables

Patients ( n)

IL-17 (pg/ml) Mean ± SD

P-value

Age (years)

  

0.343

  ≥60

38

27.08 ± 4.87

 

  <60

40

19.92 ± 5.28

 

Gender

  

0.259

  Male

36

21.23 ± 5.30

 

  Female

42

19.87 ± 5.23

 

Histologic type

  

0.491

  Adenocarcinoma

67

20.33 ± 6.12

 

  Nonadenocarcinoma

11

21.52 ± 5.05

 

ECOG PS

  

0.256

  0 or 1

50

19.99 ± 5.37

 

  2 to 4

28

21.41 ± 5.21

 

Cytologic examination

  

0.912

  Positive

60

20.46 ± 5.18

 

  Negative

18

20.62 ± 6.12

 

Stage

  

0.706

  M1a

54

20.34 ± 4.58

 

  M1b

24

20.83 ± 6.01

 

Location

  

0.751

  Right

50

20.34 ± 5.36

 

  Left

28

20.15 ± 4.97

 

aECOG PS, Eastern Cooperative Oncology Group performance status; IL-17, Interleukin 17.

Prognostic significance of pleural fluid IL-17 for lung cancer patients with malignant pleural effusion

The OS for all lung cancer patients in the current study was 6.7 months, and the 1-year survival rate was 21.8%. The prognostic significance of pleural fluid IL-17 concentration and other factors in patients with MPE was evaluated by univariate analysis (Table 3). The cutoff value chosen for pleural fluid IL-17 concentration in lung cancer patients was 15 pg/ml. High pleural fluid IL-17 concentration, older age, late-stage disease and poor ECOG PS were factors associated with poor survival. The survival time in lung cancer patients with pleural fluid IL-17 concentrations below 15 pg/ml was significantly longer than in those with higher concentrations (OS 10.8 vs. 4.7 months; P < 0.05) (Figure 3).
Table 3

Univariate analysis for overall survival in lung cancer patients with malignant pleural effusion a

Parameters

Patients ( n)

OS (months)

P-value

Age (years)

  

0.038*

  ≥60

38

5.1

 

  <60

40

9.4

 

Gender

  

0.538

  Male

36

8.7

 

  Female

42

6.2

 

IL-17 (pg/ml)

  

0.023*

  ≥15

26

4.7

 

  <15

52

10.8

 

ECOG PS

  

0.011*

  0 or 1

50

9.4

 

  2 to 4

28

3.1

 

Histologic type

  

0.617

  Adenocarcinoma

67

7.5

 

  Nonadenocarcinoma

11

5.3

 

Stage

  

0.047*

  M1a

54

8.6

 

  M1b

24

4.2

 

Location

  

0.636

  Right

50

7.3

 

  Left

28

6.9

 

aECOG PS, Eastern Cooperative Oncology Group performance status; OS, overall survival. *Significant difference.

Figure 3

Relationship between pleural fluid interleukin 17 levels and overall survival in lung cancer patients analyzed by Kaplan–Meier analysis. The survival of lung cancer patients with pleural fluid interleukin 17 (IL-17) levels <15 pg/ml was significantly longer than the survival of patients with levels ≥15 pg/ml (P < 0.05).

To test the prognostic value of pleural fluid IL-17 concentration, we performed multivariate analysis of prognostic factors using the Cox proportional hazards model. We found that pleural fluid IL-17 concentration (P = 0.007) had independent prognostic significance, whereas ECOG PS (P = 0.157), age (P = 0.545), tumor location (P = 0.362) and cancer stage (P = 0.734) lacked significant independent effects on survival (Table 4).
Table 4

Multivariate Cox proportional hazards analysis for overall survival in lung cancer patients with malignant pleural effusion a

Parameters

HR

95% CI

P- value

Age (years)

  

0.545

  ≥60

1

  

  <60

1.263

0.593 to 2.689

 

IL-17 (pg/ml)

  

0.007*

  ≥15

1

  

  <15

0.329

0.146 to 0.742

 

ECOG PS

  

0.157

  0 or 1

1

  

  2 to 4

0.653

0.778 to 4.745

 

Location

  

0.362

  Right

1

  

  Left

0.455

0.083 to 2.479

 

Stage

  

0.734

  M1a

1

  

  M1b

0.168

0.449 to 3.112

 

a95% CI, 95% confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, Hazard ratio; IL-17, Interleukin 17. *Significant difference.

Discussion

To the best of our knowledge, this study is the first on pleural effusion in which IL-17 levels were investigated for their diagnostic and prognostic power simultaneously in lung cancer patients with MPE. Our findings suggest that profoundly elevated pleural fluid concentrations of IL-17 (≥15 pg/ml) measured at the onset of effusion correlated with shorter survival in lung cancer patients. Furthermore, multivariate analysis of prognostic factors identified pleural fluid IL-17 concentration as an independent prognostic factor for OS. These results suggest that IL-17 concentration measured in pleural effusion is an indicator of not only the presence of lung cancer but also the patient’s survival outcome.

IL-17 is a proinflammatory cytokine produced mainly by CD4+ T lymphocytes. It may be important in tumor cell growth and may contribute to the aggressiveness of human tumors [24]. Recently, accumulating evidence has shown that IL-17-positive cells are frequently present in multiple cancers, including prostate cancer [25], colorectal cancer [26], hepatocellular carcinoma [27], breast cancer [28], ovarian cancer [20] and non-small-cell lung cancer [29]. Researchers in some studies have reported that IL-17 cell expression in MPE is elevated [15, 23]. Most of the reports indicate that IL-17 may protect against tumors by promoting immune system–mediated tumor rejection [30]. These results suggest the IL-17 plays an important role in tumor immune system evasion. One inference derived from this hypothesis is that IL-17 concentration in pleural effusion could be a good indicator in the follow-up of tumor patients, which is supported by our presently reported results.

Differentiating malignant from nonmalignant pleural effusion is a clinical problem, and conventional methods have proven inadequate [36]. A reliable marker for rapid and accurate diagnosis of pleural effusion is greatly needed. In this study, the IL-17 concentrations in malignant pleural effusion were higher than those in nonmalignant and TB pleural effusion. Our results suggest that IL-17 should be a tumor marker for the diagnosis of MPE. No statistically significant correlation was observed between IL-17 concentration and histological type of lung cancer. We assigned 15 pg/ml IL-17 in MPE as the diagnostic cutoff value, which had sensitivity of 79.5% and specificity of 91.1%. This result shows that IL-17 concentration could be a valuable marker in the differential diagnosis of malignant and nonmalignant pleural effusion. Further studies of the potential efficacy of this marker are needed.

Conclusion

IL-17 concentrations in MPE associated with lung cancer are significantly higher than those in nonmalignant pleural effusion. Determination of IL-17 concentration in pleural effusion is diagnostically informative and IL-17 concentration is an independent prognostic factor that shows promise in the follow-up of lung cancer patients who develop pleural effusion.

Declarations

Authors’ Affiliations

(1)
First Department of Respiratory Medicine, Nanjing Chest Hospital

References

  1. Kasahara K, Shibata K, Shintani H, Iwasa K, Sone T, Kimura H, Nobata K, Hirose T, Yoshimi Y, Katayama N, Ishiura Y, Kita T, Nishi K, Nakatsumi Y, Ryoma Y, Fujimura M, Nakao S: Randomized phase II trial of OK-432 in patients with malignant pleural effusion due to non-small cell lung cancer. Anticancer Res 2006, 26: 1495–1499.PubMedGoogle Scholar
  2. Cheng D, Liang B, Li YH: Application of MMP-7 and MMP-10 in assisting the diagnosis of malignant pleural effusion. Asian Pac J Cancer Prev 2012, 13: 505–509. 10.7314/APJCP.2012.13.2.505PubMedView ArticleGoogle Scholar
  3. Aoe K, Hiraki A, Murakami T, Eda R, Maeda T, Sugi K, Takeyama H: Diagnostic significance of interferon-γ in tuberculous pleural effusions. Chest 2003, 123: 740–744. 10.1378/chest.123.3.740PubMedView ArticleGoogle Scholar
  4. Aoe K, Hiraki A, Murakami T, Murakami K, Makihata K, Takao K, Eda R, Maeda T, Sugi K, Darzynkiewicz Z, Takeyama H: Relative abundance and patterns of correlation among six cytokines in pleural fluid measured by cytometric bead array. Int J Mol Med 2003, 12: 193–198.PubMedGoogle Scholar
  5. Hiraki A, Aoe K, Matsuo K, Murakami K, Murakami T, Onoda T, Sugi K, Takeyama H, Eda R: Simultaneous measurement of T-helper 1 cytokines in tuberculous pleural effusion. Int J Tuberc Lung Dis 2003, 7: 1172–1177.PubMedGoogle Scholar
  6. Hiraki A, Aoe K, Eda R, Maeda T, Murakami T, Sugi K, Takeyama H: Comparison of six biological markers for the diagnosis of tuberculous pleuritis. Chest 2004, 125: 987–989. 10.1378/chest.125.3.987PubMedView ArticleGoogle Scholar
  7. Sriram KB, Relan V, Clarke BE, Duhig EE, Yang IA, Bowman RV, Lee YC, Fong KM: Diagnostic molecular biomarkers for malignant pleural effusions. Future Oncol 2011, 7: 737–752. 10.2217/fon.11.45PubMedView ArticleGoogle Scholar
  8. Heffner JE: Diagnosis and management of malignant pleural effusions. Respirology 2008, 13: 5–20.PubMedView ArticleGoogle Scholar
  9. Villena V, López-Encuentra A, Echave-Sustaeta J, Martín-Escribano P, Ortuño-de-Solo B, Estenoz-Alfaro J: Diagnostic value of CA 549 in pleural fluid: comparison with CEA, CA 15.3 and CA 72.4. Lung Cancer 2003, 40: 289–294. 10.1016/S0169-5002(03)00120-XPubMedView ArticleGoogle Scholar
  10. Porcel JM, Vives M, Esquerda A, Salud A, Pérez B, Rodríguez-Panadero F: Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15–3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest 2004, 126: 1757–1763. 10.1378/chest.126.6.1757PubMedView ArticleGoogle Scholar
  11. Aoe K, Hiraki A, Yamazaki K, Nakamura Y, Murakami T, Maeda T, Nishimura M, Sugi K, Ueoka H: Elevated pleural fluid RCAS1 is a diagnostic marker and outcome predictor in lung cancer patients. Int J Oncol 2006, 29: 65–72.PubMedGoogle Scholar
  12. Su WC, Lai WW, Chen HH, Hsiue TR, Chen CW, Huang WT, Chen TY, Tsao CJ, Wang NS: Combined intrapleural and intravenous chemotherapy, and pulmonary irradiation, for treatment of patients with lung cancer presenting with malignant pleural effusion: a pilot study. Oncology 2003, 64: 18–24. 10.1159/000066516PubMedView ArticleGoogle Scholar
  13. Hsu IL, Su WC, Yan JJ, Chang JM, Lai WW: Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control. Lung Cancer 2009, 65: 371–376. 10.1016/j.lungcan.2008.12.007PubMedView ArticleGoogle Scholar
  14. Ibrahim L, Salah M, Abd El Rahman A, Zeidan A, Ragb M: Crucial role of CD4 + CD25 + FOXP3+ T regulatory cell, interferon-γ and interleukin-16 in malignant and tuberculous pleural effusions. Immunol Invest 2013, 42: 122–136. 10.3109/08820139.2012.736116PubMedView ArticleGoogle Scholar
  15. Ye ZJ, Zhou Q, Gu YY, Qin SM, Ma WL, Xin JB, Tao XN, Shi HZ: Generation and differentiation of IL-17-producing CD4+ T cells in malignant pleural effusion. J Immunol 2010, 185: 6348–6354. 10.4049/jimmunol.1001728PubMedView ArticleGoogle Scholar
  16. Yang HB, Shi HZ: T lymphocytes in pleural effusion. Chin Med J (Engl) 2008, 121: 579–580.Google Scholar
  17. Qin XJ, Shi HZ, Liang QL, Huang LY, Yang HB: CD4+CD25+ regulatory T lymphocytes in tuberculous pleural effusion. Chin Med J (Engl) 2008, 121: 581–586.Google Scholar
  18. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H: IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009, 206: 1457–1464. 10.1084/jem.20090207PubMedPubMed CentralView ArticleGoogle Scholar
  19. Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, Meeker AK, Isaacs WB, Drake CG: Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 2008, 14: 3254–3261. 10.1158/1078-0432.CCR-07-5164PubMedPubMed CentralView ArticleGoogle Scholar
  20. Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J, Wang RF: Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci U S A 2008, 105: 15505–15510. 10.1073/pnas.0710686105PubMedPubMed CentralView ArticleGoogle Scholar
  21. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G, Liu R, Zou W: Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009, 114: 1141–1149. 10.1182/blood-2009-03-208249PubMedPubMed CentralView ArticleGoogle Scholar
  22. Wang T, Lv M, Qian Q, Nie Y, Yu L, Hou Y: Increased frequencies of T helper type 17 cells in tuberculous pleural effusion. Tuberculosis (Edinb) 2011, 91: 231–237. 10.1016/j.tube.2011.02.002View ArticleGoogle Scholar
  23. Ye ZJ, Zhou Q, Zhang JC, Li X, Wu C, Qin SM, Xin JB, Shi HZ: CD39+ regulatory T cells suppress generation and differentiation of Th17 cells in human malignant pleural effusion via a LAP-dependent mechanism. Respir Res 2011, 12: 77. 10.1186/1465-9921-12-77PubMedPubMed CentralView ArticleGoogle Scholar
  24. Dong C: TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 2008, 8: 337–348. 10.1038/nri2295PubMedView ArticleGoogle Scholar
  25. Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C, Marberger MJ: Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003, 56: 171–182. 10.1002/pros.10238PubMedView ArticleGoogle Scholar
  26. Le Gouvello S, Bastuji-Garin S, Aloulou N, Mansour H, Chaumette MT, Berrehar F, Seikour A, Charachon A, Karoui M, Leroy K, Farcet JP, Sobhani I: High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 2008, 57: 772–779. 10.1136/gut.2007.123794PubMedView ArticleGoogle Scholar
  27. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, Wu C, Li SP, Zheng L: Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009, 50: 980–989. 10.1016/j.jhep.2008.12.033PubMedView ArticleGoogle Scholar
  28. Zhu X, Mulcahy LA, Mohammed RA, Lee AH, Franks HA, Kilpatrick L, Yilmazer A, Paish EC, Ellis IO, Patel PM, Jackson AM: IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res 2008, 10: R95. 10.1186/bcr2195PubMedPubMed CentralView ArticleGoogle Scholar
  29. Chen X, Wan J, Liu J, Xie W, Diao X, Xu J, Zhu B, Chen Z: Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 2010, 69: 348–354. 10.1016/j.lungcan.2009.11.013PubMedView ArticleGoogle Scholar
  30. Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautès-Fridman C, Fossiez F, Haicheur N, Fridman WH, Tartour E: Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002, 99: 2114–2121. 10.1182/blood.V99.6.2114PubMedView ArticleGoogle Scholar

Copyright

© Xu et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

Advertisement